Shi Gao Liu
Keine laufenden Positionen mehr
Vermögen: 4 Mio $ am 31.03.2024
Profil
Shi Gao Liu is the founder of two companies, Henlius Biopharmaceuticals, Inc. and Shanghai Henlius Biotech, Inc., both founded in 2009.
He held the title of President & Chief Executive Officer at Henlius Biopharmaceuticals, Inc. and Chief Executive Office & Executive Director at Shanghai Henlius Biotech, Inc. Dr. Liu received a doctorate degree from Purdue University in 1991.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2023 | 2 410 695 ( 1,48% ) | 4 Mio $ | 31.03.2024 |
Ehemalige bekannte Positionen von Shi Gao Liu
| Unternehmen | Position | Ende |
|---|---|---|
| SHANGHAI HENLIUS BIOTECH, INC. | Founder | 30.09.2020 |
Henlius Biopharmaceuticals, Inc.
 Henlius Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Henlius Biopharmaceuticals, Inc. focuses on development and commercialization of mAb-based therapeutics biosimilars and biobetter for malignant tumors and auto-immune diseases. The company was founded by Scott Liu and Paul Liu in 2009 and is headquartered in Fremont, CA. | Chief Executive Officer | - |
Ausbildung von Shi Gao Liu
| Purdue University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHANGHAI HENLIUS BIOTECH, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Henlius Biopharmaceuticals, Inc.
Henlius Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Henlius Biopharmaceuticals, Inc. focuses on development and commercialization of mAb-based therapeutics biosimilars and biobetter for malignant tumors and auto-immune diseases. The company was founded by Scott Liu and Paul Liu in 2009 and is headquartered in Fremont, CA. | Health Technology |
